Reporting of subgroup analyses from clinical trials - Author's reply

The Lancet Neurology

Volumn 11, Issue 9, 2012, Pages 747-748

  Kappos, Ludwig ^a   Devonshire, Virginia ^b   Häring, Dieter Adrian ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD;

AGE; CLINICAL TRIAL (TOPIC); HUMAN; LETTER; MULTIPLE SCLEROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT RESPONSE;

EID: 84865129327     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70183-7     Document Type: Letter

References (3)

1. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387-401.
2. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 2007, 357:2189-2194.
3. Devonshire V, Havrdova E, Radue EW, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol 2012, 11:420-428.